Payment overview · 2025
General Payments
$564.00
25 reported records · 12 companies
Healthcare provider profile · identity verified
Calvin Morgan Terrelonge, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BETHLEHEM, GA · NPI 1124236187
Verified facts
What the public records show
CMS Open Payments records show Calvin Morgan Terrelonge, M.D. received $564.00 in general payments during 2025 across 25 reported records.
Novo Nordisk Inc accounted for 34.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus, Xifaxan.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $194.91 | 34.6% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $69.15 | 12.3% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $45.32 | 8.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.63 | 7.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.86 | 7.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.51 | 7.4% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $31.56 | 5.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.97 | 4.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.99 | 3.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.45 | 3.3% | 1 | 2025 |
| Athena Bioscience, LLC | Unresolved — no canonical attribution shown | $17.42 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.23 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $564.00 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $172.86 | 7 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $69.15 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.39 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $45.32 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $41.51 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.51 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $31.56 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| Kyleena Normalized: kyleena |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| NEXICLON XR Normalized: nexiclon xr |
Drug | Athena Bioscience, LLC | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 506 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 399 | 124 |
| Hydrochlorothiazide | Hydrochlorothiazide | 286 | 84 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 268 | 79 |
| Gabapentin | Gabapentin | 262 | 68 |
| Omeprazole | Omeprazole | 258 | 74 |
| Losartan Potassium | Losartan Potassium | 233 | 72 |
| Lisinopril | Lisinopril | 232 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 217 | 59 |
| Metformin Hcl | Metformin Hcl | 209 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 188 | 60 |
| Trazodone Hcl | Trazodone Hcl | 188 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 154 | 48 |
| Famotidine | Famotidine | 141 | 40 |
| Tramadol Hcl | Tramadol Hcl | 137 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 56 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 120 | 30 |
| Sertraline Hcl | Sertraline Hcl | 116 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 29 |
| Potassium Chloride | Potassium Chloride | 104 | 35 |
| Furosemide | Furosemide | 101 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 101 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 100 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 33 |
| Allopurinol | Allopurinol | 94 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 90 | 34 |
| Carvedilol | Carvedilol | 88 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 88 | 20 |
| Ozempic | Semaglutide | 86 | 25 |
| Simvastatin | Simvastatin | 86 | 27 |
| Clonazepam | Clonazepam | 80 | 16 |
| Clonidine Hcl | Clonidine Hcl | 80 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 23 |
| Metformin Hcl Er | Metformin Hcl | 78 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 20 |
| Glipizide | Glipizide | 74 | 21 |
| Alprazolam | Alprazolam | 70 | 13 |
| Alendronate Sodium | Alendronate Sodium | 66 | 22 |
| Buspirone Hcl | Buspirone Hcl | 65 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 17 |
| Jardiance | Empagliflozin | 64 | 21 |
| Montelukast Sodium | Montelukast Sodium | 63 | 25 |
| Fenofibrate | Fenofibrate | 62 | 19 |
| Ondansetron Odt | Ondansetron | 61 | 29 |
| Diazepam | Diazepam | 60 | suppressed |
| Eliquis | Apixaban | 60 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 13 |
| Eszopiclone | Eszopiclone | 54 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 15 |
| Spironolactone | Spironolactone | 53 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 49 | 15 |
| Mirtazapine | Mirtazapine | 49 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Finasteride | Finasteride | 47 | 14 |
| Meclizine Hcl | Meclizine Hcl | 47 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 46 | 39 |
| Azithromycin | Azithromycin | 45 | 34 |
| Mounjaro | Tirzepatide | 44 | 11 |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 40 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | suppressed |
| Atenolol | Atenolol | 38 | 12 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Pregabalin | Pregabalin | 36 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | 12 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 12 |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 26 |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | 11 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Meloxicam | Meloxicam | 27 | 13 |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Oxazepam | Oxazepam | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 17 |
| Baclofen | Baclofen | 25 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 25 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 15 |
| Ulticare Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 12 |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Clozapine | Clozapine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | 12 |
| Naproxen | Naproxen | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $564.00 · 25 records | Novo Nordisk Inc | BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, Kyleena, NEXICLON XR, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, SAPIEN 3 Ultra RESILIA, The Cologuard Plus Collection Kit, VOQUEZNA, Wegovy, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error